Abstract
TAXOL1–6 is a product isolated from the Pacific yew tree (Taxus brevifolia) and is a potent microtubule-stabilizing agent which has recently been approved for treatment of otherwise intractable ovarian cancer. Despite taxol's therapeutic promise, its aqueous insolubility (<0.004 mg ml −1) hampers its clinical application. Here we report the design, synthesis and biological activity of a series of taxol-releasing compounds (protaxols) with improved pharmacological properties. These prodrugs were designed to increase their aqueous solubility and allow for taxol release under basic or physiological conditions. We demonstrate the stability of these prodrugs at pH⩽7 and their ability to release taxol in a basic medium. Taxol-like microtubule-stabilizing activity7–9 appears after the release of taxol. In vitro these prodrugs have cytotoxic properties against tumour cell lines comparable to those of taxol; moreover, human plasma catalyses the release of active taxol. These protaxols have greater potential as anticancer agents than the parent compounds taxol and taxotere (Fig. 1a).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P. & McPhail, A. T. J. Am. chem. Soc. 93, 2325–2327 (1971).
Nicolaou, K. C., Dai, W.-M. & Guy, R. K. Angew. Chem. (Int. edn) (in the press).
Poitier, P. Chem. Soc. Rev. 21, 113–119 (1992).
Swindell, C. S. Org. Chem. Prep. Proc. Int. 23, 465–543 (1991).
Kingston, D. G. I. Pharmac. Ther. 52, 1–34 (1991).
Rowinsky, E. K. & Donehower, R. C. Pharmac. Ther. 52, 35–84 (1991).
Schiff, P. B., Fant, J. & Horwitz, S. B. Nature 277, 665–667 (1979).
De Brabander, M., Geuens, G., Nuydens, R., Willebrords, R. & De Mey, J. Proc. natn. Acad. Sci. U.S.A. 78, 5608–5612 (1981).
Schiff, P. B. & Horwitz, S. B. Proc. natn. Acad. Sci. U.S.A. 77, 1561–1565 (1980).
Deutsch, H. M. et al. J. med. Chem. 32, 788–792 (1989).
Swindell, C. S., Krauss, N. E., Horwitz, S. B. & Ringel, I. J. med. Chem. 34, 1176–1184 (1991).
Zhao, Z. & Kingston, D. G. I. J. nat. Prod. 54, 1607–1611 (1991).
Mathew, A. E., Mejillano, M. R., Nath, J. P., Himes, R. H. & Stella, V. J. J. med. Chem. 35, 145–151 (1992).
Keizer, H. G. & Joenje, H. J. natn. Canc. Inst. 81, 706–709 (1989).
Skehan, P. et al. J. natn. Canc. Inst. 82, 1107–1112 (1990).
Longnecker, S. M. et al. Cancer Treat. Rep. 71, 53–59 (1987).
Merlock, R. & Wrasidlo, W. Analyt. Biochem. (in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nicolaou, K., Riemer, C., Kerr, M. et al. Design, synthesis and biological activity of protaxols. Nature 364, 464–466 (1993). https://doi.org/10.1038/364464a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/364464a0
- Springer Nature Limited
This article is cited by
-
A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer
Nature Communications (2017)
-
A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton
Investigational New Drugs (2012)
-
The Use of Amino Acid Linkers in the Conjugation of Paclitaxel with Hyaluronic Acid as Drug Delivery System: Synthesis, Self-Assembled Property, Drug Release, and In Vitro Efficiency
Pharmaceutical Research (2010)
-
Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer
European Journal of Nuclear Medicine and Molecular Imaging (2008)
-
Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death
Cancer Chemotherapy and Pharmacology (1995)